At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
DM-101 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Subcutaneous Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
In Brief
A Phase 1 clinical trial evaluating DM-101 and Placebo to match DM-101 for Birch Pollen Allergy. Completed, enrolled 27 participants across 1 site.
Detailed Summary
Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBirch Pollen Allergy
CountriesFinland
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartFeb 2020
First PostedFeb 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedFeb 12, 2020
Enrollment StartFeb 11, 2020
Primary CompletionMay 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.4 years ago
Interventions
DM-101biological
DM-101 administered by subcutaneous (SC) injection
Placebo to match DM-101biological
Placebo to match DM-101 administered by SC injection